2023-05-09 07:20:46 ET
- Mersana Therapeutics press release ( NASDAQ: MRSN ): Q1 GAAP EPS of -$0.52 misses by $0.09 .
- Revenue of $7.8M (+284.2% Y/Y) misses by $10.49M .
- Net cash used in operating activities for the first quarter of 2023 was $29.0 million.
- Cash, cash equivalents and marketable securities as of March 31, 2023 were $273.9 million, compared to cash and cash equivalents of $280.7 million as of December 31, 2022.
- Mersana expects that its available funds will be sufficient to support its operating plan commitments into the second half of 2024.
For further details see:
Mersana Therapeutics GAAP EPS of -$0.52 misses by $0.09, revenue of $7.8M misses by $10.49M